<DOC>
	<DOCNO>NCT01458574</DOCNO>
	<brief_summary>The study propose ass whether compare placebo , CP-690,550 effective , safe , tolerable maintenance therapy subject Ulcerative Colitis ( UC ) . The study propose ass whether compare placebo , CP-690,550 maintenance therapy effectively achieve mucosal heal improves quality life subject UC.The study propose assess CP-690,550 pharmacokinetic exposure maintenance therapy subject age 18 year UC .</brief_summary>
	<brief_title>A Study Of Oral CP-690,550 As A Maintenance Therapy For Ulcerative Colitis</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Tofacitinib</mesh_term>
	<criteria>Subjects meet study entry criterion complete 8week induction treatment Study A3921094 A3921095 Subjects achieve clinical response Study A3921094 A3921095 Women childbearing potential must test negative pregnancy prior study enrollment Subjects willing able comply schedule visit , treatment plan , laboratory test , study procedure Evidence personally sign date informed consent document ( ) indicate subject ( legally acceptable representative ) inform pertinent aspect study . Subjects major protocol violation ( determine Sponsor ) Study A3921094 A3921095 Presence indeterminate colitis , microscopic colitis , ischemic colitis , infectious colitis , clinical finding suggestive Crohn 's disease Subjects surgery UC opinion investigator , likely require surgery UC study period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Janus kinase inhibitor</keyword>
	<keyword>JAK 3 inhibitor</keyword>
	<keyword>inflammatory bowel disease</keyword>
	<keyword>ulcerative colitis</keyword>
	<keyword>OCTAVE</keyword>
	<keyword>CP-690</keyword>
	<keyword>550</keyword>
	<keyword>tofacitinib</keyword>
	<keyword>Xeljanz</keyword>
</DOC>